Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis.

Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM

Oncogene1 Feb 2000Cited by 55 (Europe PMC)

PMID10702797DOI10.1038/sj.onc.1203386PepBankPUB-10702797

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

01AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
Nonlactating multiparous WAP-DES mice exhibited mammary interepithelial neoplasia with constitutive transgene expression.
In plain wordsIn mice, des(1‑3)hIGF-I transgene expression accompanied mammary precancerous lesions.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
Not applicableMammary interepithelial neoplasia
Study
mousen: not reported in source
WAP-DES transgenic mice
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Nonlactating, multiparous WAP-DES mice exhibited hyperplastic lesions termed mammary interepithelial neoplasia (MIN) which constitutively expressed WAP-DES.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279701
02AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
By 23 months, 53% of WAP-DES mice developed mammary adenocarcinomas.
In plain wordsIn mice with the des(1‑3)hIGF-I transgene, 53% developed mammary cancers by 23 months.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
Not applicableMammary adenocarcinoma incidence
Study
mousen: not reported in source
WAP-DES transgenic mice
Outcome group
Tumor growth · Cancer
Measurements
Incidence
53%
WAP-DES mice by 23 months
Source sentences
Summary
By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279702
03AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
Normal mammary glands of WAP-DES mice showed a 75% reduction in apoptosis.
In plain wordsIn mice with the des(1‑3)hIGF-I transgene, normal mammary glands showed reduced cell death.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseMammary apoptosis
Study
mousen: not reported in source
WAP-DES transgenic mice
Outcome group
Tumor growth · Cancer
Measurements
Apoptosis reduction
75%
normal mammary glands of WAP-DES mice
Source sentences
Summary
A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279703
04AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
Normal mammary glands of WAP-DES mice showed a 75% reduction in proliferation.
In plain wordsIn mice with the des(1‑3)hIGF-I transgene, normal mammary glands showed reduced cell proliferation.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseMammary proliferation
Study
mousen: not reported in source
WAP-DES transgenic mice
Outcome group
Tumor growth · Cancer
Measurements
Proliferation reduction
75%
normal mammary glands of WAP-DES mice
Source sentences
Summary
A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279704
05AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to WAP-DES mice.
In plain wordsIn mice, adding mutant p53 to the des(1‑3)hIGF-I transgene gave similar mammary tumor incidence.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
No significant changeTumor incidence versus WAP-DES
Study
mousen: not reported in source
WAP-DES/p53 bitransgenic mice
Comparator
WAP-DES mice
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2 - 3-fold greater than that of nontransgenic and p53172R-H females.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279705
06AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
WAP-DES/p53 bitransgenic mice had 2 - 3-fold greater mammary tumor incidence than nontransgenic females.
In plain wordsIn mice, both transgenes together produced greater mammary tumor incidence than in nontransgenic females.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseTumor incidence versus nontransgenic mice
Study
mousen: not reported in source
WAP-DES/p53 bitransgenic mice
Comparator
nontransgenic females
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2 - 3-fold greater than that of nontransgenic and p53172R-H females.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279706
07AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
WAP-DES/p53 bitransgenic mice had 2 - 3-fold greater mammary tumor incidence than p53172R-H females.
In plain wordsIn mice, both transgenes together produced greater mammary tumor incidence than mutant p53 alone.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseTumor incidence versus mutant p53 mice
Study
mousen: not reported in source
WAP-DES/p53 bitransgenic mice
Comparator
p53172R-H females
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2 - 3-fold greater than that of nontransgenic and p53172R-H females.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279707
08AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
Tumor latency was 8 months shorter in bitransgenic mice than in the other three genotypes.
In plain wordsIn mice, both transgenes together shortened tumor latency compared with the other three genotypes.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseTumor latency
Study
mousen: not reported in source
WAP-DES/p53 bitransgenic mice
Comparator
other three genotypes
Outcome group
Tumor growth · Cancer
Measurements
Tumor latency reduction
8 months
bitransgenic mice versus the other three genotypes
Source sentences
Summary
Tumor latency, however, was reduced by 8 months in bitransgenic mice as compared to mice of the other three genotypes.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279708
09AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
Aneuploidy occurred frequently in bitransgenic and mutant p53 tumors, but not in tumors expressing only WAP-DES.
In plain wordsIn mice, tumors with mutant p53 frequently had abnormal chromosome numbers, unlike tumors with only the des(1‑3)hIGF-I transgene.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
MixedTumor aneuploidy
Study
mousen: not reported in source
WAP-DES/p53 bitransgenic, p53172R-H, and WAP-DES transgenic mice
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Aneuploidy was frequently observed in tumors from bitransgenic and p53172R-H mice, but not from mice expressing only the WAP-DES transgene.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279709
10AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
Tumor IGFBP3 expression was elevated in WAP-DES mice but not in bitransgenic mice.
In plain wordsIn mice, tumor IGFBP3 expression increased with the des(1‑3)hIGF-I transgene alone, but not with both transgenes.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
MixedTumor IGFBP3 expression
Study
mousen: not reported in source
WAP-DES and WAP-DES/p53 bitransgenic mice
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Expression of IGFBP3 was elevated in tumors from WAP-DES, but not bitransgenic mice, indicating an alteration in the p53/IGF-I axis.
1 context sentence(design, population, supporting numbers)
Summary · context
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H).
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1070279710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 2
21 Oct 2026, 13:52 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis.

Summary

Results from this study10

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms